326 related articles for article (PubMed ID: 22236250)
1. Exploring activity cliffs in medicinal chemistry.
Stumpfe D; Bajorath J
J Med Chem; 2012 Apr; 55(7):2932-42. PubMed ID: 22236250
[No Abstract] [Full Text] [Related]
2. From activity cliffs to activity ridges: informative data structures for SAR analysis.
Vogt M; Huang Y; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1848-56. PubMed ID: 21761918
[TBL] [Abstract][Full Text] [Related]
3. A data mining method to facilitate SAR transfer.
Wassermann AM; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1857-66. PubMed ID: 21774471
[TBL] [Abstract][Full Text] [Related]
4. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
Dimova D; Hu Y; Bajorath J
J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
[TBL] [Abstract][Full Text] [Related]
5. Modeling of activity landscapes for drug discovery.
Bajorath J
Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
[TBL] [Abstract][Full Text] [Related]
6. Monitoring global growth of activity cliff information over time and assessing activity cliff frequencies and distributions.
Stumpfe D; Bajorath J
Future Med Chem; 2015 Aug; 7(12):1565-79. PubMed ID: 26334207
[TBL] [Abstract][Full Text] [Related]
7. Editorial: Delving into the Fundamental Aspects of Drug-Receptor Interaction.
Basak SC; Kier LB
Curr Comput Aided Drug Des; 2017; 13(2):87-90. PubMed ID: 29517468
[No Abstract] [Full Text] [Related]
8. Method for the evaluation of structure-activity relationship information associated with coordinated activity cliffs.
Dimova D; Stumpfe D; Bajorath J
J Med Chem; 2014 Aug; 57(15):6553-63. PubMed ID: 25014781
[TBL] [Abstract][Full Text] [Related]
9. Activity cliffs in drug discovery: Dr Jekyll or Mr Hyde?
Cruz-Monteagudo M; Medina-Franco JL; Pérez-Castillo Y; Nicolotti O; Cordeiro MN; Borges F
Drug Discov Today; 2014 Aug; 19(8):1069-80. PubMed ID: 24560935
[TBL] [Abstract][Full Text] [Related]
10. inSARa: intuitive and interactive SAR interpretation by reduced graphs and hierarchical MCS-based network navigation.
Wollenhaupt S; Baumann K
J Chem Inf Model; 2014 Jun; 54(6):1578-95. PubMed ID: 24850242
[TBL] [Abstract][Full Text] [Related]
11. Do medicinal chemists learn from activity cliffs? A systematic evaluation of cliff progression in evolving compound data sets.
Dimova D; Heikamp K; Stumpfe D; Bajorath J
J Med Chem; 2013 Apr; 56(8):3339-45. PubMed ID: 23527828
[TBL] [Abstract][Full Text] [Related]
12. Activity cliffs: facts or artifacts?
Medina-Franco JL
Chem Biol Drug Des; 2013 May; 81(5):553-6. PubMed ID: 23375049
[TBL] [Abstract][Full Text] [Related]
13. Large-scale similarity search profiling of ChEMBL compound data sets.
Heikamp K; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1831-9. PubMed ID: 21728295
[TBL] [Abstract][Full Text] [Related]
14. Can we accelerate medicinal chemistry by augmenting the chemist with Big Data and artificial intelligence?
Griffen EJ; Dossetter AG; Leach AG; Montague S
Drug Discov Today; 2018 Jul; 23(7):1373-1384. PubMed ID: 29577971
[TBL] [Abstract][Full Text] [Related]
15. The opportunities of mining historical and collective data in drug discovery.
Wassermann AM; Lounkine E; Davies JW; Glick M; Camargo LM
Drug Discov Today; 2015 Apr; 20(4):422-34. PubMed ID: 25463034
[TBL] [Abstract][Full Text] [Related]
16. Quo vadis, virtual screening? A comprehensive survey of prospective applications.
Ripphausen P; Nisius B; Peltason L; Bajorath J
J Med Chem; 2010 Dec; 53(24):8461-7. PubMed ID: 20929257
[No Abstract] [Full Text] [Related]
17. Evolution of the activity cliff concept for structure-activity relationship analysis and drug discovery.
Bajorath J
Future Med Chem; 2014 Sep; 6(14):1545-9. PubMed ID: 25367389
[No Abstract] [Full Text] [Related]
18. Metal complexes in medicinal chemistry: new vistas and challenges in drug design.
Thompson KH; Orvig C
Dalton Trans; 2006 Feb; (6):761-4. PubMed ID: 16437168
[TBL] [Abstract][Full Text] [Related]
19. Conserved core substructures in the overlay of protein-ligand complexes.
Finzel BC; Akavaram R; Ragipindi A; Van Voorst JR; Cahn M; Davis ME; Pokross ME; Sheriff S; Baldwin ET
J Chem Inf Model; 2011 Aug; 51(8):1931-41. PubMed ID: 21736376
[TBL] [Abstract][Full Text] [Related]
20. Drug discovery FAQs: workflows for answering multidomain drug discovery questions.
Chichester C; Digles D; Siebes R; Loizou A; Groth P; Harland L
Drug Discov Today; 2015 Apr; 20(4):399-405. PubMed ID: 25463038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
